HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GPI 1046

structure given in first source

Also Known As:

3-(3-pyridyl)-1-propyl-(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate; GPI-1046

Networked: 12 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - GPI 1046: 12

Experts

1.	Li, Song: 2 articles (12/2007 - 08/2006)
2.	Burnett, Arthur L: 2 articles (06/2007 - 05/2005)
3.	Steiner, Joseph P: 2 articles (06/2007 - 03/2007)
4.	Hakroush, Samy: 1 article (01/2018)
5.	Kalluri, Raghu: 1 article (01/2018)
6.	Kauffels, Anne: 1 article (01/2018)
7.	Klöpper, Friederike: 1 article (01/2018)
8.	Lorf, Thomas: 1 article (01/2018)
9.	Müller, Gerhard A: 1 article (01/2018)
10.	Nyamsuren, Gunsmaa: 1 article (01/2018)

Related Diseases

1.	Wounds and Injuries (Trauma) 01/01/2018 - "Direct targeting of FKBP12/YY1 with in vivo morpholino approaches or small molecule inhibitors, including GPI-1046, was equally effective for inducing ARNT expression, with subsequent activation of ALK3-dependent canonical BMP-signaling responses and attenuated chronic organ failure in models of chronic kidney disease, and also cardiac and liver injuries. " 08/15/2006 - "Prompted by the therapeutic potential of the neuroimmunophilin FK506-binding protein (FKBP) ligand, GPI-1046, in the treatment of nerve injuries and neurodegenerative diseases, a novel series of non-cyclic derivatives of GPI-1046 were designed and synthesized. "
2.	Chronic Renal Insufficiency 01/01/2018 - "Direct targeting of FKBP12/YY1 with in vivo morpholino approaches or small molecule inhibitors, including GPI-1046, was equally effective for inducing ARNT expression, with subsequent activation of ALK3-dependent canonical BMP-signaling responses and attenuated chronic organ failure in models of chronic kidney disease, and also cardiac and liver injuries. "
3.	Atrophy 09/18/1999 - "In the present study, we investigated whether chronic systemic treatment with GPI 1046 could affect the decline of spatial learning and memory, and the atrophy of medial septal cholinergic neurons, associated with late senescence in C57 black mice. " 09/18/1999 - "Systemic treatment with GPI 1046 improves spatial memory and reverses cholinergic neuron atrophy in the medial septal nucleus of aged mice."
4.	Infarction (Infarctions) 05/01/2004 - "In contrast to cases treated with vehicle, the infarct volume was reduced greatly and rotamase activity was inhibited significantly at 24 hr of reperfusion by treatment with GPI-1046. " 07/24/2000 - "FK506 and rapamycin decreased infarct volume by 40% and 37%, respectively, whereas GPI-1046 was ineffective. " 05/01/2004 - "The present results suggest that GPI-1046 significantly decreased infarct volume and provided neuroprotective effect on rats after transient focal cerebral ischemia by inhibiting the increase of rotamase activity and of the number of FKBP12-, FKBP52-, caspase-8-, cytochrome c-, and caspase-3-positive cells in the ischemic area."
5.	Brain Ischemia (Cerebral Ischemia) 05/01/2004 - "The present results suggest that GPI-1046 significantly decreased infarct volume and provided neuroprotective effect on rats after transient focal cerebral ischemia by inhibiting the increase of rotamase activity and of the number of FKBP12-, FKBP52-, caspase-8-, cytochrome c-, and caspase-3-positive cells in the ischemic area." 07/24/2000 - "The neuroprotective effects of FK506, rapamycin and GPI-1046 were also tested in a rodent model of permanent focal cerebral ischemia. "

Related Drugs and Biologics

1.	Morpholinos
2.	Tacrolimus Binding Protein 1A (FKBP12)
3.	Ligands
4.	Immunophilins
5.	Neuroprotective Agents
6.	GPI 1046
7.	Cytochromes c (Cytochrome c)
8.	Amino Acid Transport System X-AG (Glutamate Transporter)
9.	Tacrolimus Binding Proteins (FKBP)
10.	Nerve Growth Factor (NGF)

Related Therapies and Procedures

1.	Prostatectomy (Retropubic Prostatectomy)